NAFLD-Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse by Debes, J.D. et al.
1EDITORIAL | Hepatology, Vol. 0, No. 0, 2020 
NAFLD-Related Hepatocellular 
Carcinoma and the Four Horsemen of the 
Apocalypse
SEE ARTICLE ON PAGE XXXX
Nonalcoholic fatty liver disease (NAFLD) has become the most important cause of chronic liver disease in the United States, affecting 25% 
of adults in the country. The rest of the world does not 
lag behind. The Americas, Asia, and the Middle East 
show higher rates of NAFLD than the United States, 
and Europe and Africa suffer a rapid escalation of “fatty 
livers.”(1) Just as it is evident that control of NAFLD 
currently represents one of the biggest challenges in 
liver disease, it is also evident that NAFLD represents 
a large spectrum of diseases and that the progression to 
cirrhosis and hepatocellular carcinoma (HCC) occurs 
in a minority of affected individuals. Identifying those 
individuals to better monitor and screen them as well 
as understand the underlying mechanisms of disease 
progression in that setting is a highly relevant issue 
and one the scientific community is eager to define. 
It is in this context that Kanwal et al.(2) in this issue 
of Hepatology, evaluated the role of metabolic traits 
in the progression of NAFLD to cirrhosis and HCC. 
Their findings expose a “hepatocalyptic” resemblance 
to a modern-day four horsemen, with diabetes, obesity, 
dyslipidemia, and hypertension all contributing together 
and independently to the destruction of the liver.
Obesity alone is associated with increased overall 
mortality from all cancers, and HCC is no exception. 
However, the presence of obesity and dyslipidemia in 
the setting of NAFLD has a unique impact in the 
liver. Both maladies increase lipid accumulation, with 
subsequent generation of reactive oxygen species and 
endothelial reticulum stress, all of which leads to 
inflammation and fibrosis.(3) Moreover, obesity leads 
to dysregulation of leptin, a hormone released in rela-
tion to satiety that contributes to the production of 
a catabolic state.(4) Alterations in leptin regulation 
can lead to insulin resistance, with an aggressive form 
of hepatic steatosis as well as an increase in adipo-
cyte production of tumor necrosis factor-α (TNF-α), 
a proinflammatory cytokine related to liver fibrosis 
and HCC. TNF-α can induce activation of c-Jun 
N-terminal kinase, leading to impairment of the nor-
mal insulin receptor signaling, as well as interact with 
nuclear factor kappa B to promote the transcription 
of genes involved in apoptosis, inflammation, prolifer-
ation, and angiogenesis.(4) An obesity-related increase 
in the insulin-like growth factor has also been asso-
ciated directly with the promotion of HCC through 
modulation of cell growth and migration.(3,5)
Hypertension as such is unlikely to lead to fibrosis 
progression or HCC development and likely represents 
an expression of the conundrum of the metabolic syn-
drome. However, the association of hypertension with 
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NAFLD is of dramatic significance; after all, the most 
common cause of death in individuals with NAFLD 
is cardiovascular disease.(6)
Diabetes represents a unique horseman because it 
can significantly increase progression to HCC alone 
as well as dramatically augment the effects of the 
other metabolic traits. In the study by Kanwal et al.(2) 
diabetes had the strongest association with HCC, a 
finding reported by multiple groups, including the 
authors.(7,8) It is thought that all the insulin-related 
pathogenic events mentioned above, including insulin- 
like growth factor signaling pathway modulation, con-
tribute to the effect of diabetes on HCC progression 
in the setting of NAFLD. Diabetes also promotes 
hepatocarcinogenesis through activation of inflam-
matory cascades with production of proinflammatory 
cytokines, which cause genomic instability and inhibit 
apoptosis of hepatocytes.(9) In addition, associations 
with bacterial translocation and increased iron depo-
sition in the setting of diabetes and NAFLD can also 
exacerbate the progression to cirrhosis and HCC.(3) 
Indeed, although most studies suggest that modify-
ing the endocrine impact of diabetes with metformin 
or statins improves liver health in this setting, the 
underlying mechanisms are far from clear.(3,10)
A unique aspect of Kanwal et al.’s study is the 
association of obesity,(2) dyslipidemia, and particularly 
diabetes with noncirrhotic HCC development. Most 
theories of HCC development, diabetes, and obesity 
relate to inflammatory models; therefore, this finding 
brings to light the need for further research aimed to 
understand the molecular aspects related to noncir-
rhotic HCC in the setting of NAFLD. Interestingly, 
a recent European study found an inverse association 
between noncirrhotic HCC and the presence of dia-
betes, which leads to speculation that epigenetic and 
environmental variables play a major role in the inter-
relation between diabetes, NAFLD, and HCC.(11)
In the quest to identify a specific cohort of indi-
viduals to follow closely for the early identification 
of liver-related complications, the authors propose to 
focus on individuals with multiple metabolic traits. 
This represents a reasonable initial approach, but an 
approach faced with the dilemma of having a popula-
tion that is still too large to focus on. Approximately 
40%-70% of individuals with diabetes have evidence 
of NAFLD.(1) In the study by Kanwal et al.(2) that 
number was closer to 40%. Because of the nature and 
interrelation of diabetes with obesity, hypertension, 
and dyslipidemia, a large number of these individuals 
will present multiple traits. In the study, approximately 
20% of participants had all four traits. However, indi-
viduals were initially identified for inclusion based on 
elevated liver enzymes, likely leaving a much higher 
number of participants with steatosis findings associ-
ated with diabetes with unclear prognosis. Moreover, 
those with lean NAFLD or of different ethnic origin 
will likely have risk factors not taken into account in 
this study.
More importantly, the study highlights the need for 
a better understanding of the effect of metabolic traits 
in HCC development and the need for multinational 
and multiethnic cohorts. The study by Kanwal et al.(2) 
was performed in a mainly white male population of 
veterans with NAFLD identified by elevated liver 
enzymes. Indeed, 95% of study participants were men, 
and 69% of these men were white. The mean body 
mass index in the population was 31.
Overall, the findings get clinicians a step closer to 
a better stratification of individuals with NAFLD who 
are at risk for complications. Sadly, the complex cascade 
of events leading to NAFLD-related complications 
and the vast range of diseases that are grouped into 
what we call “NAFLD” will require further and deeper 
research to identify the most destructive horsemen.
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